Complement C4B protein in schizophrenia

References

• Blanchong CA, Chung EK, Rupert KL, et al. Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int Immunopharmacol 2001; 1: 365–392
   PubMed Web of Science ®Google Scholar
• Blanchong CA, Zhou B, Rupert KL, et al. Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease. J Exp Med 2000; 191: 2183–2196
   PubMed Web of Science ®Google Scholar
• Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001; 58: 1032–1037
   PubMed Web of Science ®Google Scholar
• Carroll MC, Belt T, Palsdottir A, Porter RR. Structure and organization of the C4 genes. Phil Trans R Soc London B Biol Sci 1984; 306: 379–388
   PubMedGoogle Scholar
• Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998; 16: 545–568
   PubMedGoogle Scholar
• Chrispeels J, Bank S, Rittner C, Bitter-Suermann D. Sandwich enzyme-linked immunosorbent assays for quantitation of the C4 isotypes (C4A and C4B) in human plasma. J Immunol Methods 1989; 125: 5–12
   PubMedGoogle Scholar
• Colten HR, Rosen FS. Complement deficiencies. Annu Rev Immunol 1992; 10: 809–834
   PubMed Web of Science ®Google Scholar
• Gaughran F. Immunity and schizophrenia: autoimmunity, cytokines, and immune responses. Int Rev Neurobiol 2002; 52: 275–302
   PubMedGoogle Scholar
• Giles CM, Fielder AH, Lord DK, Robson T, O'Neill GJ. Two monoclonal anti-C4d reagents react with epitopes closely related to Rg:1 and Ch:1. Immunogenetics 1987; 26: 309–312
   PubMedGoogle Scholar
• Hakobyan S, Boyajyan A, Sim RB. Classical pathway complement activity in schizophrenia. Neurosci Lett 2005; 374: 35–37
   PubMed Web of Science ®Google Scholar
• Hauptmann G, Tappeiner G, Schifferli JA. Inherited deficiency of the fourth component of human complement. Immunodefic Rev 1988; 1: 3–22
   PubMedGoogle Scholar
• Hinze-Selch D. Infection, treatment and immune response in patients with bipolar disorder versus patients with major depression, schizophrenia or healthy controls. Bipolar Disord 2002; 4(Suppl 1)81–83
   PubMedGoogle Scholar
• Hohler T, Stradmann-Bellinghausen B, Starke R, et al. C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol 2002; 37: 387–392
   PubMed Web of Science ®Google Scholar
• Isenman DE, Young JR. The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement component C4. J Immunol 1984; 132: 3019–3027
   PubMed Web of Science ®Google Scholar
• Johnson SA, Pasinetti GM, Finch CE. Expression of complement C1qB and C4 mRNAs during rat brain development. Brain Res Dev Brain Res 1994; 80: 163–174
   PubMedGoogle Scholar
• Jones AL, Mowry BJ, Pender MP, Greer JM. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunol Cell Biol 2005; 83: 9–17
   PubMed Web of Science ®Google Scholar
• Jones B, Rantakallio P, Hartikainen AL, Isohanni M, Sipila P. Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications. Am J Psychiatry. 1998; 155: 355–364
   PubMed Web of Science ®Google Scholar
• Law SK, Dodds AW. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 1997; 6: 263–274
   PubMed Web of Science ®Google Scholar
• Law SKA, Reid KBM. Complement. IRL Press at Oxford University Press, Oxford 1995
   Google Scholar
• Law SK, Dodds AW, Porter RR. A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J 1984; 3: 1819–1823
   PubMed Web of Science ®Google Scholar
• Marenco S, Weinberger DR. The neurodevelopmental hypothesis of schizophrenia. Dev Psychopathol 2000; 12: 501–527
   PubMed Web of Science ®Google Scholar
• Mayilyan K, Presanis JS, Arnold JN, Soghoyan AF, Sim RB. Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neurosci Lett 2006; 404: 336–341
   PubMed Web of Science ®Google Scholar
• Muller N. Immunological and infectious aspects of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004; 254: 1–3
   PubMed Web of Science ®Google Scholar
• O'Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, et al. Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001; 166: 4154–4162
   PubMedGoogle Scholar
• Rantakallio P, Jones P, Moring J, Von Wendt L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses. Int J Epidemiol 1997; 26: 837–843
   PubMed Web of Science ®Google Scholar
• Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005; 10: 434–449
   PubMed Web of Science ®Google Scholar
• Roos MH, Mollenhauer E, Demant P, Rittner C. A molecular basis for the two locus model of human complement component C4. Nature 1982; 298: 854–856
   PubMedGoogle Scholar
• Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 2001; 15: 319–339
   PubMed Web of Science ®Google Scholar
• Rudduck C, Beckman L, Franzen G, Jacobsson L, Lindstrom L. Complement factor C4 in schizophrenia. Hum Hered 1985; 35: 223–226
   PubMedGoogle Scholar
• Schroers R, Nothen MM, Rietschel M, et al. Investigation of complement C4B deficiency in schizophrenia. Hum Hered 1997; 47: 279–282
   PubMed Web of Science ®Google Scholar
• Shcherbakova I, Neshkova E, Dotsenko V, Platonova T, Shcherbakova E, Yarovaya G. The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. Immunopharmacology 1999; 43: 273–279
   PubMed Web of Science ®Google Scholar
• Spivak B, Radwan M, Brandon J, et al. Reduced total complement haemolytic activity in schizophrenic patients. Psychol Med 1993; 23: 315–318
   PubMed Web of Science ®Google Scholar
• van Beek J, Elward K, Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann NY Acad Sci 2003; 992: 56–71
   PubMed Web of Science ®Google Scholar
• van Beek J, van Meurs M, ‘t Hart BA, et al. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. J Immunol 2005; 174: 2353–2365
   PubMed Web of Science ®Google Scholar
• Warren RP, Burger RA, Odell D, Torres AR, Warren WL. Decreased plasma concentrations of the C4B complement protein in autism. Arch Pediatr Adolesc Med 1994; 148: 180–183
   PubMedGoogle Scholar
• Warren RP, Odell JD, Warren WL, Burger RA, Maciulis A, Torres AR. Is decreased blood plasma concentration of the complement C4B protein associated with attention-deficit hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry 1995a; 34: 1009–1014
   PubMedGoogle Scholar
• Warren RP, Yonk J, Burger RW, Odell D, Warren WL. DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein. Neuropsychobiology 1995b; 31: 53–57
   PubMed Web of Science ®Google Scholar
• World Health Organization. Schedule for Clinical Assessment in Neuropsychiatry. WHO, Geneva 1992
   Google Scholar
• World Health Organization. The Composite International Diagnostic Interview: Core Version 2.1. WHO, Geneva 1997
   Google Scholar
• Yang Y, Chung EK, Zhou B, et al. Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index. J Immunol 2003; 171: 2734–2745
   PubMed Web of Science ®Google Scholar
• Yang Z, Mendoza AR, Welch TR, Zipf WB, Yu CY. Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletions and disease associations. J Biol Chem 1999; 274: 12147–12156
   PubMedGoogle Scholar
• Yu CY, Chung EK, Yang Y, et al. Dancing with complement C4 and the RP-C4-CYP21-TNX (RCCX) modules of the major histocompatibility complex. Prog Nucleic Acid Res Mol Biol 2003; 75: 217–292
   PubMedGoogle Scholar